These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26050556)

  • 21. Phosphodiesterase inhibition in cognitive decline.
    García-Barroso C; Ugarte A; Martínez M; Rico AJ; Lanciego JL; Franco R; Oyarzabal J; Cuadrado-Tejedor M; García-Osta A
    J Alzheimers Dis; 2014; 42 Suppl 4():S561-73. PubMed ID: 25125473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
    Kim NN
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.
    Chen S; Yan C
    Expert Opin Drug Discov; 2021 Feb; 16(2):183-196. PubMed ID: 32957823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential role of IP3/Ca
    Jyoti Dutta B; Singh S; Seksaria S; Das Gupta G; Bodakhe SH; Singh A
    Biochem Pharmacol; 2022 Jul; 201():115071. PubMed ID: 35525328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's).
    Moraca F; Negri A; de Oliveira C; Abel R
    J Chem Inf Model; 2019 Jun; 59(6):2729-2740. PubMed ID: 31144815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Phosphodiesterase-Inhibiting Fraction from Roasted Coffee (Coffea arabica) through Activity-Guided Fractionation.
    Röhrig T; Liesenfeld D; Richling E
    J Agric Food Chem; 2017 May; 65(19):3792-3800. PubMed ID: 28443667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells.
    Dragicevic N; Delic V; Cao C; Copes N; Lin X; Mamcarz M; Wang L; Arendash GW; Bradshaw PC
    Neuropharmacology; 2012 Dec; 63(8):1368-79. PubMed ID: 22959965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information.
    Prickaerts J; Sik A; van Staveren WC; Koopmans G; Steinbusch HW; van der Staay FJ; de Vente J; Blokland A
    Neurochem Int; 2004 Nov; 45(6):915-28. PubMed ID: 15312986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
    Reneerkens OA; Rutten K; Steinbusch HW; Blokland A; Prickaerts J
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):419-43. PubMed ID: 18709359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
    Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDE inhibition and cognition enhancement.
    Blokland A; Menniti FS; Prickaerts J
    Expert Opin Ther Pat; 2012 Apr; 22(4):349-54. PubMed ID: 22475506
    [No Abstract]   [Full Text] [Related]  

  • 38. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
    Lerner A; Epstein PM
    Biochem J; 2006 Jan; 393(Pt 1):21-41. PubMed ID: 16336197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.